Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

NCT01197170 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

277

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors
Advanced Cancer

Interventions

DRUG: Anastrozole
DRUG: Bevacizumab
DRUG: Everolimus
DRUG: Sorafenib
DRUG: Erlotinib

Sponsor

M.D. Anderson Cancer Center